Restricted accessResearch articleFirst published online 2023-11
A randomized controlled trial of Vitamin D supplementation in Iranian patients with schizophrenia: Effects on serum levels of glycogen synthase kinase‐3β and symptom severity
Growing evidence has shown that hypovitaminosis D is a risk factor for developing schizophrenia and comorbid conditions. Therefore, this study aimed to examine the effect of vitamin D supplementation on serum levels of vitamin D, metabolic factors related to insulin resistance (IR) and the severity of the disorder in patients with schizophrenia.
Methods
Forty-eight chronic male patients with schizophrenia with vitamin D deficiency (≤20 ng/mL= (≤50 nmol/l) were selected and randomly assigned to vitamin D treatment and placebo groups. Subjects were supplemented for 8 weeks with vitamin D (2000 IU/day) or placebo.
Results
Within-group comparison revealed that the vitamin D group had a significant reduction in waist circumference, Positive and Negative Syndrome Scale – total score (PANSS-TS), and glycogen synthase kinase 3 beta (GSK-3β) levels (P = .022, P = <.001 and P = .013, respectively). On the other hand, the placebo group showed a significant increase in the level of fasting serum insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (P = .003 and P = .003). The between-group comparison showed a significant difference in terms of PANSS-TS, GSK-3β, fasting serum insulin (FSI), and HOMA-IR (P = .022, P = .048, P = .013 and P = .014 respectively).
Conclusions
Among vitamin D deficient patients with schizophrenia, vitamin D supplementation may affect GSK-3 β, an important biomarker in schizophrenia and insulin resistance. In addition, vitamin D supplementation in such patients may reduce the disorder’s symptom severity.
TandonRKeshavanMSNasrallahHA. Schizophrenia,“just the facts” what we know in 2008. 2. Epidemiology and etiology. Schizophrenia research. 2008;102(1-3):1-18.
2.
TripathiAKarSKShuklaR. Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies. Clinical Psychopharmacology and Neuroscience. 2018;16(1):7.
3.
Hennig-FastK. EPA-1074–Neurobiology of interaction of emotion and cognition in schizophrenia. Eur Psychiatr. 2014;29(1):1.
4.
McGrathJSaariKHakkoH, et al.Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophrenia research. 2004;67(2-3):237-245.
5.
McGrathJJEylesDWPedersenCB, et al.Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch Gen Psychiatr. 2010;67(9):889-894.
6.
KulaksizogluSKulaksizogluB. The relationship between metabolic syndrome, BDNF, and vitamin D in patients with schizophrenia. Neurochemical Journal. 2017;11(1):104-111.
7.
WrzosekMŁukaszkiewiczJWrzosekM, et al.Vitamin D and the central nervous system. Pharmacol Rep. 2013;65(2):271.
8.
EylesDWBurneTHMcGrathJJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol. 2013;34(1):47-64.
9.
KesbyJPTurnerKMAlexanderSEylesDWMcGrathJJBurneTH. Developmental vitamin D deficiency alters multiple neurotransmitter systems in the neonatal rat brain. Int J Dev Neurosci. 2017;62:1-7.
10.
Gezen-AkDDursunEYilmazerS. The effect of vitamin D treatment on nerve growth factor (NGF) release from hippocampal neurons. Nöro Psikiyatri Arşivi. 2014;51(2):157.
11.
EylesDWSmithSKinobeRHewisonMMcGrathJJ. Distribution of the vitamin D receptor and 1α-hydroxylase in human brain. J Chem Neuroanat. 2005;29(1):21-30.
12.
KesbyJPCuiXBurneTHEylesDW. Altered dopamine ontogeny in the developmentally vitamin D deficient rat and its relevance to schizophrenia. Front Cell Neurosci. 2013;7:111.
13.
SchoenrockSTarantinoL. Developmental vitamin D deficiency and schizophrenia: the role of animal models. Gene Brain Behav. 2016;15(1):45-61.
14.
BivonaGAgnelloLBelliaC, et al.Non-skeletal activities of vitamin D: from physiology to brain pathology. Medicina. 2019;55(7):341.
15.
EylesDAlmerasLBenechP, et al.Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. J Steroid Biochem Mol Biol. 2007;103(3-5):538-545.
16.
McGrathJJBurneTHFéronFMackay-SimAEylesDW. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophr Bull. 2010;36(6):1073.
17.
SmoldersJSchuurmanKGMEvS, et al.Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis—affected brain tissue. J Neuropathol Exp Neurol. 2013;72(2):91-105.
18.
LimaLALopesMJPCostaRO, et al.Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats. J Neuroinflammation. 2018;15(1):1-11.
19.
PatrickRPAmesBN. Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. Faseb J. 2014;28(6):2398-2413.
20.
KavianiMNikooyehBZandHYaghmaeiPNeyestaniTR. Effects of vitamin D supplementation on depression status, selected pro-inflammatory biomarkers and neurotransmitters in depressive patients: a study protocol. Nutrition and Food Sciences Research. 2019;6(4):1-7.
21.
ZhuJ-LLuoW-WChengXLiYZhangQ-ZPengW-X. Vitamin D deficiency and schizophrenia in adults: a systematic review and meta-analysis of observational studies. Psychiatr Res. 2020;288:112959.
22.
SnellerMHDe BoerNEveraarsS, et al.Clinical, biochemical and genetic variables associated with metabolic syndrome in patients with schizophrenia spectrum disorders using second-generation antipsychotics: a systematic review. Front Psychiatr. 2021;12:625935.
LiuXYaoZ. Chronic over-nutrition and dysregulation of GSK3 in diseases. Nutrition & metabolism. 2016;13(1):1-18.
25.
BakiLShioiJWenP, et al.PS1 activates PI3K thus inhibiting GSK‐3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 2004;23(13):2586-2596.
26.
FangXYuSXLuYBastRCWoodgettJRMillsGB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA. 2000;97(22):11960.
27.
NadriCKozlovskyNAgamGBersudskyY. GSK-3 parameters in lymphocytes of schizophrenic patients. Psychiatr Res. 2002;112(1):51.
28.
LiZChenPChenJ, et al.Glucose and insulin-related traits, type 2 diabetes and risk of schizophrenia: a Mendelian randomization study. EBioMedicine. 2018;34:182.
29.
ZhangXZanelloLP. Vitamin D receptor–dependent 1α, 25 (OH) 2 vitamin D3–induced anti‐apoptotic PI3K/AKT signaling in osteoblasts. J Bone Miner Res. 2008;23(8):1238-12348.
30.
ZaulkffaliASMd RazipNNSyed AlwiSS, et al.Vitamins D and E stimulate the PI3K-AKT signalling pathway in insulin-resistant SK-N-SH neuronal cells. Nutrients. 2019;11(10):2525.
31.
KozlovskyNRegenoldWLevineJRapoportABelmakerRAgamG. GSK-3β in cerebrospinal fluid of schizophrenia patients. Journal of neural transmission. 2004;111(8):1093.
32.
NadriCDeanBScarrEAgamG. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophrenia research. 2004;71(2-3):377-382.
33.
KozlovskyNBelmakerRAgamG. Low GSK-3β immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatr. 2000;157(5):831.
34.
EmamianESHallDBirnbaumMJKarayiorgouMGogosJA. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat Genet. 2004;36(2):131.
35.
EmamianE. AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci. 2012;5:33.
36.
LeuchtSKaneJMKisslingWHamannJEtschelEEngelRR. What does the PANSS mean?Schizophrenia research. 2005;79(2-3):231.
37.
MatthewsDRHoskerJPRudenskiASNaylorBTreacherDFTurnerRC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412.
38.
GrahamKKeefeRLiebermanJCalikogluALansingKPerkinsD. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first‐episode schizophrenia. Early intervention in psychiatry. 2015;9(5):397-405.
39.
KrivoyAOnnRVilnerY, et al.Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled clinical trial. EBioMedicine. 2017;26:138-145.
40.
GoswamiRGuptaNRayDSinghNTomarN. Pattern of 25-hydroxy vitamin D response at short (2 month) and long (1 year) interval after 8 weeks of oral supplementation with cholecalciferol in Asian Indians with chronic hypovitaminosis D. Br J Nutr. 2008;100(3):526.
41.
MalabananAVeronikisI. Redefining vitamin D insufficiency. Lancet. 1998;351(9105):805.
42.
GaughranFStringerDWojewodkaG, et al.Effect of vitamin D supplementation on outcomes in people with early psychosis: the DFEND randomized clinical trial. JAMA Netw Open. 2021;4(12):e2140858.
43.
YükselRNAltunsoyNTikirB, et al.Correlation between total vitamin D levels and psychotic psychopathology in patients with schizophrenia: therapeutic implications for add-on vitamin D augmentation. Therapeutic advances in psychopharmacology. 2014;4(6):268-275.
44.
GhaderiABanafsheHRMirhosseiniN, et al.Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients. BMC Psychiatr. 2019;19(1):77.
45.
EylesDFeronFCuiX, et al.Developmental vitamin D deficiency causes abnormal brain development. Psychoneuroendocrinology. 2009;34:S247-S257.
46.
OumaSSuenagaMBölükbaşı HatipFFHatip‐Al‐KhatibITsuboiYMatsunagaY. Serum vitamin D in patients with mild cognitive impairment and Alzheimer's disease. Brain and Behavior. 2018;8(3):e00936.
47.
LaruelleMKegelesLSAbi-DarghamA. Glutamate, dopamine, and schizophrenia. Ann NY Acad Sci. 2003;1003:138-158.
48.
KesbyJEylesDMcGrathJScottJ. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry. 2018;8(1):1-12.
49.
KarimahARahayuKS. The role of vitamin d deficiency towards cognitive deficit of schizophrenia. EurAsia J BioSci. 2020;14(1). 1833-1837.
50.
SteinbergJLGarverDLMoellerFGRaeseJDOrsulakPJ. Serum homovanillic acid levels in schizophrenic patients and normal control subjects. Psychiatr Res. 1993;48(2):93-106.
51.
HarveyLBurneTCuiXMackay-SimAEylesDMcGrathJ. Vitamin D and the brain: a neuropsychiatric perspective. Clin Rev Bone Miner Metabol. 2009;7(2):199-205.
52.
PertileRACuiXHammondLEylesDW. Vitamin D regulation of GDNF/Ret signaling in dopaminergic neurons. Faseb J. 2018;32(2):819-828.
53.
ZhangTZhuLNiT, et al.Voltage-gated calcium channel activity and complex related genes and schizophrenia: a systematic investigation based on Han Chinese population. J Psychiatr Res. 2018;106:99-105.
54.
ErkSMeyer-LindenbergALindenDE, et al.Replication of brain function effects of a genome-wide supported psychiatric risk variant in the CACNA1C gene and new multi-locus effects. Neuroimage. 2014;94:147-154.
55.
HashimotoKFukushimaTShimizuE, et al.Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatr. 2003;60(6):572.
56.
AmaralADCalhauCCoelhoR. Schizophrenia: implications of vitamin D deficit on brain development. IJCNMH. 2014;1(16):1-14.
57.
LaruelleM. Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol. 2014;14:97-102.
58.
KesbyJPBurneTHMcGrathJJEylesDW. Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: an animal model of schizophrenia. Biol Psychiatr. 2006;60(6):591.
59.
KesbyJPCuiXO’LoanJMcGrathJJBurneTHEylesDW. Developmental vitamin D deficiency alters dopamine-mediated behaviors and dopamine transporter function in adult female rats. Psychopharmacology. 2010;208(1):159-168.
60.
EylesDBurneTMcGrathJ. Vitamin D in fetal brain development. In Seminars in Cell & Developmental Biology. Amsterdam, Netherlands: Elsevier; 2011.
61.
GarcionESindjiLLeblondelGBrachetPDarcyF. 1, 25‐Dihydroxyvitamin D3 regulates the synthesis of γ‐glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem. 1999;73(2):859-866.
62.
HughesPJLeeJSReinerNEBrownG. The vitamin D receptor‐mediated activation of phosphatidylinositol 3‐kinase (PI3Kα) plays a role in the 1α, 25‐dihydroxyvitamin D3‐stimulated increase in steroid sulphatase activity in myeloid leukaemic cell lines. J Cell Biochem. 2008;103(5):1551-1572.
63.
BorgesCCSallesAFBringhentiISouza‐MelloVMandarim‐de‐LacerdaCAAguilaMB. Adverse effects of vitamin D deficiency on the Pi3k/Akt pathway and pancreatic islet morphology in diet‐induced obese mice. Mol Nutr Food Res. 2016;60(2):346-357.
64.
LiuX. Overstimulation can create health problems due to increases in PI3K/Akt/GSK3 insensitivity and GSK3 activity. SpringerPlus. 2014;3(1):356.
65.
KararJMaityA. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51.
66.
ZhouHLiX-MMeinkothJPittmanRN. Akt regulates cell survival and apoptosis at a postmitochondrial level. The Journal of cell biology. 2000;151(3):483-494.
67.
SzamosiAKelemenOKériS. Hippocampal volume and the AKT signaling system in first-episode schizophrenia. J Psychiatr Res. 2012;46(3):279-284.
68.
van BeverenNJBuitendijkGHSwagemakersS, et al.Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients. PLoS One. 2012;7(2):e32618.
69.
JoaquimHPZanettiMVSerpaMH, et al.Increased platelet glycogen sysnthase kinase 3beta in first-episode psychosis. Schizophrenia research. 2018;195:402.
70.
ByrneJHVoogtMTurnerKMEylesDWMcGrathJJBurneTH. The impact of adult vitamin D deficiency on behaviour and brain function in male Sprague-Dawley rats. PLoS One. 2013;8(8):e71593.
71.
GrovesNJKesbyJPEylesDWMcGrathJJMackay-SimABurneTH. Adult vitamin D deficiency leads to behavioural and brain neurochemical alterations in C57BL/6J and BALB/c mice. Behav Brain Res. 2013;241:120-131.
72.
LiXZhuWRohM-SFriedmanABRosboroughKJopeRS. In vivo regulation of glycogen synthase kinase-3 β (GSK3 β) by serotonergic activity in mouse brain. Neuropsychopharmacology. 2004;29(8):1426-1431.
73.
BeaulieuJ-MGainetdinovRRCaronMG. The Akt–GSK-3 signaling cascade in the actions of dopamine. Trends in pharmacological sciences. 2007;28(4):166-172.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
